Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on ...

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Associated Therapies: -

Clinical Trials

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ACT-246475
Drug: Clopidogrel
Drug: Prasugrel
Drug: Placebo
Drug: Ticagrelor

First Posted Date: 2018-02-13

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 77

Registration Number: NCT03430661

Locations: 🇺🇸
Biotrial Inc, Newark, New Jersey, United States

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Phase 4

Conditions: Cardiopulmonary Arrest With Successful Resuscitation
ACS - Acute Coronary Syndrome
Hypothermia, Induced

Interventions: Drug: Cangrelor
Drug: Placebo
Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2017-09-06

Last Posted Date: 2017-09-13

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 60

Registration Number: NCT03273075

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response

Phase 4

Withdrawn

Conditions: Diabetes Mellitus

Interventions: Drug: Ticagrelor
Drug: Prasugrel

First Posted Date: 2017-01-23

Last Posted Date: 2020-07-15

Lead Sponsor: CirQuest Labs, LLC

Registration Number: NCT03027934

Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Phase 4

Completed

Conditions: STEMI - ST Elevation Myocardial Infarction
Coronary Artery Disease

Interventions: Drug: Cangrelor
Drug: Tirofiban
Drug: Prasugrel

First Posted Date: 2016-11-30

Last Posted Date: 2020-02-21

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 122

Registration Number: NCT02978040

Locations: 🇨🇭
Bern University Hospital, Bern, Switzerland
🇮🇹
University of Ferrara, Ferrara, Italy
🇮🇹
University of Naples Federico II, Naples, Italy

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban
Drug: Clopidogrel
Drug: Prasugrel
Drug: Vitamin K antagonist
Drug: Ticagrelor

First Posted Date: 2016-08-15

Last Posted Date: 2020-05-06

Lead Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Target Recruit Count: 1506

Registration Number: NCT02866175

Locations: 🇺🇦
Kharkiv City Clinical Hospital #8, Kharkiv, Ukraine
🇬🇧
Altnagelvin Area Hospital, Londonderry, United Kingdom
🇬🇧
Golden Jubilee Hospital, Clydebank, United Kingdom

and more 197 locations

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Phase 4

Completed

Conditions: Myocardial Infarction
Angioplasty, Balloon, Coronary
Platelet Aggregation Inhibitors

Interventions: Drug: Prasugrel
Drug: Ticagrelor

First Posted Date: 2016-06-22

Last Posted Date: 2017-08-11

Lead Sponsor: Faculty Hospital Kralovske Vinohrady

Target Recruit Count: 1226

Registration Number: NCT02808767

Locations: 🇨🇿
Faculty Hospital Kralovske Vinohrady, Prague, Czechia

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Phase 4

Completed

Conditions: Cardiovascular Diseases

Interventions: Drug: Ticagrelor
Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2015-10-27

Last Posted Date: 2017-02-13

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 54

Registration Number: NCT02587260

Locations: 🇨🇭
Inselspitäl University Medical Center, Bern, Switzerland
🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇮🇹
Policlinico San Matteo, Pavia, Italy

and more 2 locations

Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Phase 4

Terminated

Conditions: Angina Pectoris

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2015-09-14

Last Posted Date: 2020-07-17

Lead Sponsor: LMU Klinikum

Target Recruit Count: 795

Registration Number: NCT02548611

Locations: 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
🇩🇪
Munich University Hospital, Munich, Bavaria, Germany
🇩🇪
Klinikum Bogenhausen, Munich, Germany

and more 2 locations

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Prasugrel
Drug: Vorapaxar
Drug: Aspirin
Drug: Ticagrelor

First Posted Date: 2015-09-10

Last Posted Date: 2020-09-16

Lead Sponsor: University of Florida

Target Recruit Count: 130

Registration Number: NCT02545933

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Ticagrelor vs. Prasugrel Effects on Infarct Size

Phase 2

Withdrawn

Conditions: Cardiovascular Disease

Interventions: Drug: ticagrelor
Drug: prasugrel
Drug: Placebo

First Posted Date: 2015-07-23

Last Posted Date: 2016-05-04

Lead Sponsor: Yochai Birnbaum

Registration Number: NCT02507323

Locations: 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸
Memorial Hermann Hospital, Houston, Texas, United States
🇺🇸
Baylor-St. Lukes Medical Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy